The show profiled the biotech company's brain tumour vaccine ICT-107, which is in Phase 2b clinical trials to treat patients with glioblastoma multiforme, an aggressive brain cancer.
ImmunoCellular's Phase 2 trial is a double-blind and placebo-controlled study aimed to evaluate the safety and efficacy of the vaccine.
The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology.
Sanjay Gupta, a practicing neurosurgeon, reports on health and medical news for Starting Point with Soledad O'Brien, Anderson Cooper 360 and anchors the weekend medical affairs program during the weekends.
A transcript of the CNN show can be accessed, by clicking this link: http://edition.cnn.com/TRANSCRIPTS/1208/11/hcsg.01.html
In late July, the biotech company said the U.S. Food and Drug Administration gave clearance to start Phase I clinical trials of ICT-121, a vaccine that targets an antigen expressed in tumours.
The trial, which will be performed at a Los Angeles-based medical centre, will test the vaccine on 20 patients with glioblastoma multiforme, an aggressive brain cancer.
Like ICT-107, now in Phase II trials treating subjects with the same type of brain cancer, the ICT-121 treatment is the second dendritic cell-based vaccine to enter the clinic.
Both brain tumour vaccines work by turning a patient's immune system against tumour associated antigens. This is done by
pulling out dendritic cells and loading them with antigens. The cells, then, are reinserted into the patient's body to trigger an immune response.
The company seeks to develop and sell new therapeutics using the immune system to fight cancer. ImmunoCellular is based in Los Angeles.